



## PRIVATE FUNDING OPPORTUNITIES: APR 27, 2018

Please contact Corporate & Foundation Relations in the Office of Development at [devcfr@mgh.harvard.edu](mailto:devcfr@mgh.harvard.edu) if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

### 1. Request for Basic Scientific & Clinical Research Proposals, ASXL Rare Research Endowment Foundation **New**

The ASXL family consists of ASXL1/Bohring-Opitz Syndrome, ASXL2/Shashi-Pena Syndrome, and ASXL3/Bainbridge-Ropers Syndrome. Many children have global developmental delays (e.g. cannot sit, walk, talk, feed themselves) and complex medical issues including severe neurological and respiratory issues. Most individuals are completely dependent on caretakers for every aspect of their care.

These children have complex clinical issues and often see specialists who do not have the knowledge or experience to properly manage their care due to the rarity and unknowns of their syndrome. There are few evidence-based publications for reference and significant unknowns about the mechanisms behind ASXL syndromes.

Bohring-Opitz Syndrome (BOS/ASXL1), Bainbridge-Ropers syndrome (BRS/ASXL3), and Shashi-Pena Syndrome (SPS/ASXL2) are under diagnosed due to challenges recognizing the diagnosis, shortage of genetics services, and the cost of genetic testing.

ARRE will support basic scientific and clinical research that can further characterize the molecular causes and pathogenicity of the ASXL gene family, improve medical care plans, and meet the needs for families who face extraordinary challenges and uncertainty.

Through research, ARRE aims to improve the quality of life for these individuals and their families:

- Prevent health risks through early identification
- Improve existing options through research



---

Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <[arobb@mgh.harvard.edu](mailto:arobb@mgh.harvard.edu)> to schedule an individual consultation or group training session.

- Inform parents and caretakers so that they can better advocate for the care their child needs

Highest priority will be given to pilot projects to test new ideas about pathogenesis and therapeutics of ASXL congenital syndromes and clinical research studies. Of particular interest to the ARRE are studies related to respiratory illness, cyclic vomiting, seizures, sleep issues, and identification of treatments that impact the daily life of people with ASXL syndromes and their families.

Award Amount: Up to \$100,000 per year for 1-2 years

Indirect Costs: 10%

Proposal Deadline: Sep 15, 2018

Website: <https://www.arrefoundation.org/request-for-proposals/>

## **2. ADDF-Harrington Scholar Program, Alzheimer's Drug Discovery Foundation (ADDF)**

The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. The goal of developing new therapies will be achieved by providing award recipients with both research funding and committed project support by a team of pharmaceutical industry experts within the Harrington Discovery Institute Innovation Support Center. The Innovation Support Center's Advisory Panel is staffed by drug development experts who have held senior management positions in established pharmaceutical companies. They have significant experience in commercial drug development, have broad, established networks, and collectively span a wide range of knowledge in drug discovery and development.

Novel targets are highly encouraged. Current target areas of interest include, but are not limited to:

- Neuroprotection
- Inflammation
- Vascular function
- Mitochondria & metabolic function
- Proteostasis
- ApoE
- Epigenetics
- Synaptic activity & neurotransmitters

The ADDF-Harrington Scholar Program does not support anti-amyloid (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitor approaches.

Award Amount: Up to \$600,000 paid over 2 years

Indirect Costs: None

LOI Deadline: May 25, 2018

Website: <http://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington>

### **3. Allergan Foundation Research Grant, American Academy of Optometry (AAO)/American Optometric Foundation (AOF)**

To support talented optometry and vision science faculty and researchers in the area of glaucoma or the anterior segment, the American Academy of Optometry Foundation (AAOF) is now accepting proposals for one research grant sponsored by The Allergan Foundation.

Award Amount: \$60,000 for 1 year plus a \$750 travel grant

Indirect Costs: None

Application Deadline: Jul 15, 2018

Website: <https://www.aaopt.org/home/aaof/programs/programs-faculty/programs-faculty-allergan>

### **4. Faculty Innovation in Education Award, American Board of Psychiatry and Neurology, Inc. New**

The ABPN Faculty Innovation in Education Award (formerly the Faculty Fellowship Award) is intended to support the development of innovative education and/or evaluation projects that promote effective residency/fellowship training or lifelong learning of practicing psychiatrists and neurologists. Preference will be given to projects that have the potential for use in more than one site and to applicants who are at a junior or mid-faculty level.

Award Amount: \$100,000 paid over 2 years

Indirect Costs: None

Application Deadline: Aug 3, 2018

Website: <https://www.abpn.com/about/abpn-awards-program/>

### **5. Early Stage Investigator Seed Grants (ESI Seed Grants), Antibacterial Resistance Leadership Group (ARLG) New**

Each year, direct costs will be provided to up to early stage investigators (ESIs) for research in areas related to antibacterial resistance (AR). The purpose of the ESI Seed Grant is to allow researchers to generate preliminary data leading to additional external funding.

ESI Seed Grants can be used to support initial research in any area related to AR. Importantly, these funds can be used to give ESIs access to strains contained in the ARLG Virtual Biorepository Strain Catalogue.

Priority areas include:

- Gram-negative Bacterial Infections
- Antimicrobial Stewardship and Infection Prevention
- Gram-positive Bacterial Infections
- Diagnostics and Devices
- Special Populations
- Pediatrics
- Pharmacokinetics

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Questionnaire Deadline: Continuous

Website: <https://arlg.org/how-to-apply/esi-seed-grant-applicants>

## **6. ARLG Fellowships, Antibacterial Resistance Leadership Group (ARLG) New**

The ARLG Fellowship is up to 2-years, fully funded, competitive opportunity to acquire expertise in antibacterial resistance clinical research. The ARLG fellowship is designed for infectious disease fellows interested in pursuing research, training and a subsequent career in the patient-oriented study of antibiotic resistance. Recipients will be integrated into the ARLG mission and programs.

Priority areas include:

- Gram-negative Bacterial Infections
- Antimicrobial Stewardship and Infection Prevention
- Gram-positive Bacterial Infections
- Diagnostics and Devices
- Special Populations
- Pediatrics
- Pharmacokinetics

Award Amount: Salary for 2 years

Indirect Costs: None

Questionnaire Deadline: Continuous

Website: <https://arlg.org/how-to-apply/arlg-fellowships>

## **7. Clinical Studies - Research Concept Proposal, Antibacterial Resistance Leadership Group (ARLG) New**

The Antibacterial Resistance Leadership Group (ARLG) seeks proposals for clinical studies (e.g., randomized controlled trials, case-control studies or cohort studies) to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. Ideal studies: (1) have the potential to transform medical practice and (2) would be unlikely to occur without ARLG support. Studies

of pharmacokinetics, pharmacodynamics or studies in selected populations (e.g., immunocompromised hosts, patients in long-term care settings, neonates, overweight or obese children) are encouraged.

Applications that propose pre-clinical or non-clinical research, studies of non-bacterial pathogens, or research not directly related to antibiotic resistance will be considered non-responsive.

The ARLG has prioritized four areas of research and is currently soliciting clinical studies to the following:

1. Infections Caused by Gram-negative Bacteria
  - Develop and test antimicrobial agents or strategies for Gram-negative infections in adults or children caused by multiple-drug resistance gram-negative bacilli including carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant bacteria.
  - Evaluate novel agents or strategies to prevent emergence of resistance during treatment of infections caused by Gram-negative bacilli.
  - Optimize administration of antimicrobial agents for treatment of Gram-negative infections with respect to dose, dosing interval, and duration of therapy in adults or children.
2. Infections Caused by Gram-positive Bacteria
  - Investigate strategies or therapies, including narrow-spectrum oral antimicrobials, for treatment of infections predominantly caused by Gram-positive bacteria, including skin and soft tissue infections, bone and joint infections, and bacteremia in adults and children.
  - Compare the effectiveness of linezolid and daptomycin or other antibiotics alone or in combination with other agents for infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin resistant enterococci (VRE).
  - Optimize administration of antimicrobial agents for treatment of Gram-positive infections with respect to dose, dosing interval, and duration of therapy in adults or children.
3. Infection Control/Stewardship
  - Assess antibacterial stewardship strategies for non-use or early discontinuation of antibacterial therapy to reduce emergence and spread of antibiotic resistant bacteria.
  - Evaluate transmission dynamics or emergence of carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant Gram-negative bacilli in healthcare and community settings.
  - Examine strategies (e.g., stewardship, decolonization, probiotics) to prevent occurrence or recurrence or reduce the risk of resistant Gram-negatives, *Clostridium difficile* infection, VRE, or MRSA.
4. Diagnostics
  - Evaluate methods or platforms, which may include biomarkers or host-response markers (e.g., "omics") to rapidly identify bacterial pathogens and infections.

Approaches could include simple and rapid point-of-care diagnostics to detect drug resistance, guide antibacterial therapy, or support clinical trials.

- Evaluate rapid, accurate methods for antimicrobial susceptibility testing of cultured bacteria.

Award Amount: Unspecified

Indirect Costs: Unspecified

Questionnaire Deadline: Continuous

Website: <https://arlg.org/how-to-apply>

### **8. Investigator-Institution Initiated Research, Bayer AG/Bayer USA Foundation**

Bayer Healthcare is interested in receiving and reviewing Investigator-Institution Initiated Research grant proposals related to research in our therapeutic areas. Applications for support are generally reviewed monthly.

The Bayer Radiology Investigator Initiated Research program focuses on research in the following areas:

- Contrast-enhanced MRI
- Contrast delivery devices for CT and MRI
- Informatics for Radiology practice management including radiation dose monitoring, contrast dose and patient protocols

The Pharmaceuticals Investigator-Institution Initiated Research is interested in receiving and reviewing Investigator-Institution Initiated Research grant proposals related to research in the areas of:

- Dermatology
- Radiology
- Gynecologic Therapies
- Hematology
- Multiple Sclerosis
- Oncology

Award Amount: Unspecified

Indirect Costs: Unspecified

Proposal Deadline: Continuous

Website: <http://www.grants-contributions.bayer.com/en/home/index.php>

### **9. Young Investigator Grants, Breast Cancer Alliance (BCA)**

The mission of the Breast Cancer Alliance is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure.

To promote these goals, we invest in innovative research, breast surgery fellowships, regional education, dignified support and screening for the underserved.

To encourage a commitment to breast cancer research, the Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer research, and who are in the early stages of their career, to apply for funding for the Young Investigator Grant.

The research project must be directly related to the field of breast cancer. Areas of relevant research may include but are not limited to: diagnosis, etiology, immunology, genetics, therapies, prevention and clinical studies.

Award Amount: \$125,000 paid over 2 years

Indirect Costs: 8%

Application Deadline: Jul 20, 2018

Website: <http://breastcanceralliance.org/grants/>

#### **10. Clinic and Laboratory Integration Program (CLIP) Grants, Cancer Research Institute (CRI)**

The Cancer Research Institute funds research aimed at furthering the development of immunological approaches to the diagnosis, treatment, and prevention of cancer. The Institute's mission is to bring effective immune system-based therapies to cancer patients sooner.

To this end, CRI offers its Clinic and Laboratory Integration Program (CLIP) Grants to qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program supports basic, pre-clinical, and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic.

Award Amount: \$200,000 paid over 2 years

Indirect Costs: None

LOI Deadline: Nov 1, 2018

Website: <https://cancerresearch.org/scientists/fellowships-grants/translational-research-grants>

#### **11. Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) - SCIRTS Senior Research Grants, Craig H. Neilsen Foundation**

Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) portfolio funding is intended to support research designed to improve understanding and advance the treatment of acute and chronic SCI and to fill gaps in the field, including mechanistic, preclinical, translational and/or clinical studies.

SCIRTS Senior Research Grants focus on highly innovative projects by established contributors to explore new areas of SCI research or fill important gaps in the SCI field. The goal is not to substitute for federal funding, but to use Neilsen Foundation funds to encourage cutting-edge ideas and approaches that have great potential, despite some additional risk. The importance of the research goal should balance the risk due to the early stage of innovation. Criteria include the innovative nature of the proposed research, the likelihood that success will move the field forward, and a history of productivity and significant contributions by the investigator.

NOTE: Early phase clinical trials of novel investigational drug or cell/biologic interventions under regulation by the U.S. Food and Drug Administration are limited to the Senior Grant category. Postdoctoral fellows may participate in an approved trial supported by the Mentor's other funding.

Award Amount: \$600,000 paid over 3 years

Indirect Costs: 10%

LOI Deadline: May 4, 2018

Website: <http://chnfoundation.org/spinal-cord-injury-research-on-the-translational-spectrum/>

## **12. Basic Research Grant Program, International Rett Syndrome Foundation**

Basic research studies are discovery-based and aim to identify novel translational targets. These will aim to determine the mechanism or black box at the synapse, glia, etc. (feedback/feedforward mechanisms). Basic research studies may have a common link between basic and translational research programs. For example, they identify mechanism or molecular targets of successful drug(s) in clinical trials. Basic research studies may identify genetic modifiers and novel targets. Basic research studies may investigate whether oxidative/cellular stress is a causal or secondary effect of Rett syndrome.

Award Amount: \$150,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: May 25, 2018

Website: <https://www.rettsyndrome.org/for-researchers/grant-programs/research-grant-opportunities>

## **13. Clinical Research Program, International Rett Syndrome Foundation New**

These applications will undergo a 2-Tier Review Process: (1) Standard initial RSO review, (2) NHS consortium review & feedback on both the science as well as the practicality of execution

1. NHS Pilot Project Grants, with defined scope as small scale trials, facilitated through NHS Network sites. Projects types may include:

- Outcome measures
- Biomarkers, including wearables and medical devices



- Behavioral or therapy interventions
- Pragmatic trials that may require a multi-disciplinary approach in methodology (e.g. a neurologist, PT and AAC specialist) where trial outcome aims to improve QOL.

2. Neuro-rehabilitation and translational studies that have been funded through the HeART mechanism and have published their results will now need to validate their results in other locations. It is our intention to have these validation studies carried out at the clinical sites associated with the Natural History Study. We are looking for applications that will move initial positive observations from single labs/single investigators into a multi-site environment. To participate in this venue, it is necessary for the original P.I. to establish a relationship with at least two of the Natural History sites to conduct the validation study.

Award Amount: \$50,000-\$150,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: May 25, 2018

Website: <https://www.rettsyndrome.org/for-researchers/grant-programs/research-grant-opportunities>

#### **14. Mentored Training Fellowship Program, International Rett Syndrome Foundation**

Rettsyndrome.org announces the availability of Mentored Training Fellowships to support scientists in both basic and clinical research in the field of Rett syndrome so that they become successful, independent basic research scientists and clinical investigators. The Mentored Training fellowships are designed to assist post-doctoral and clinical scientist researcher in training to establish careers in fields relevant to Rett syndrome research.

Rettsyndrome.org encourages novel basic research programs for these fellowships within the following emphasis areas:

- Understanding the role of MeCP2 during normal brain development
- Characterizing the role of MeCP2, including MeCP2 target genes, in normal structure and function of the developing and adult nervous system
- Determination of the relationship between patterns of expression of MeCP2, FoxG1, CDKL5, and related proteins in the nervous system and the neurologic and behavioral phenotypes of patients with RTT and/or related animal models
- The investigation of neuronal abnormalities that result from MeCP2 dysfunction
- The role of microglial and macroglial cells in development as it relates to RTT
- Understanding mechanisms and systems leading to aberrant behavior in RTT

Award Amount: \$100,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: May 25, 2018

Website: <https://www.rettsyndrome.org/research/funding-opportunities>

### **15. Neuro-Habilitation Program, International Rett Syndrome Foundation**

Communication challenges are issues that are one of the largest issues for families of those with a Rett syndrome child. We request applications to improve communication. The spectrum of opportunities in regard to communication is wide, and we will entertain letters of intent covering a wide variety of ideas.

Research in healthcare delivery is needed. One challenge with Rett syndrome is that not all families are close to recognized Rett clinics. Best practices could be delivered via telemedicine technologies. We are looking for applications that objectively measure the gain of function using new telemedicine technologies. Therapies need to be published showing clinical benefit, to be used as evidence for insurance and pediatric/adult care access to services.

Award Amount: \$150,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: May 25, 2018

Website: <https://www.rettsyndrome.org/for-researchers/grant-programs/research-grant-opportunities>

### **16. Translational Research Program, International Rett Syndrome Foundation**

As we continue to look for drugs that can help correct the biology associated with Rett syndrome, we are in need of a screening system that can evaluate a large number of compounds quickly and efficiently. Today we use the Scout Program to evaluate drug candidates but because the Scout Program is an in vivo model screen it is limited in the number of drugs we can screen in a year. We would like to receive letters of intent that develop an in vitro screen that can screen large libraries leading to families of molecules that could be moved into an in vivo screen.

Award Amount: \$150,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: May 25, 2018

Website: <https://www.rettsyndrome.org/for-researchers/grant-programs/research-grant-opportunities>

### **17. Greater Value Portfolio, Patrick and Catherine Weldon Donaghue Medical Research Foundation**

The Greater Value Portfolio grant program will fund research projects for the purpose of creating new approaches to achieving a higher value healthcare system. The goal of this program is to test new approaches and tools that organizations can readily use to improve the value of the healthcare they provide to their patients and communities.

For 2018, the Greater Value Portfolio program will place greater emphasis on research that is closely linked to ongoing improvement initiatives that are geared to achieving greater healthcare value in organizations that deliver healthcare services.

The Foundation believes value in healthcare is achieved with uniformly high quality outcomes and favorable patient experience for the money we spend. Symptoms of poor healthcare value include high and rising healthcare costs, unwarranted variation in prices, unacceptable variation in quality, and a lack of transparency in both price and outcomes. Investigators conducting research that expect to develop actionable solutions to one or more of these symptoms of low value healthcare are encouraged to apply to the Greater Value Portfolio program.

Eligible topics include research that advances promising strategies in these areas:

- Reduce routine treatments, tests, and screenings for patients for whom the potential harms (including financial harm) outweigh potential benefits
- Provide tools to help consumers make decisions about their healthcare based on value in addition to other patient-centered factors
- Promote conversations between patients with serious illnesses and their clinicians about preferences and trade-offs related to alternative treatment options
- Reduce structural barriers and inefficiencies that impede improving value within systems or across healthcare settings
- Test models of care and coverage that address current financial disincentives for systemic change (i.e., paying for current programs with future savings or paying for programs that address social determinants of health with the savings from lowering expenditures related to clinical services)

Award Amount: \$400,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: May 3, 2018

Website: <http://donaghue.org/grant-programs/grant-opportunities/>

### **18. Brain Tumor Research Grants Research Grant, Pediatric Low Grade Astrocytoma Foundation (PLGA)**

A Kids' Brain Tumor Cure, a national non-profit organization, was founded in 2007 by a group of dedicated parents, physicians and friends to improve the treatment, quality of life, and long-term outlook for children with brain tumors through research, support, education, and advocacy.

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. Our hope is that this research will lead to a better understanding of the causes of PLGA as well as

the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

Award Amount: Unspecified

Indirect Costs: None

LOI Deadline: Continuous

Website: <http://akidsbraintumorcure.org/medical-research-on-childhood-brain-tumors/apply-for-a-plga-sponsored-grant/>